12-Week Wearable-Monitored Workplace Exercise Program for Office Workers
NCT07924592, Not applicable, Not yet recruiting, Mahidol University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | 12-Week Wearable-Monitored Workplace Exercise Program for Office Workers | ClinicalTrials.gov |
| NCT number | NCT07924592 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 78 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Mahidol University | ClinicalTrials.gov |
| Conditions | Office Workers | ClinicalTrials.gov |
| Interventions | Wearable-Monitored Workplace Exercise Program, Educational Session and Sitting Self-Monitoring | ClinicalTrials.gov |
| First posted | 2026-11-09 | ClinicalTrials.gov |
| Last updated | 2026-11-09 | ClinicalTrials.gov |
Registered outcomes 22
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Resting and Active Motor Thresholds (RMT and AMT) Copy | Baseline (Week 0) and post-intervention (Week 13) | Resting motor threshold (RMT) and active motor threshold (AMT) are assessed using transcranial magnetic stimulation (TMS) and recorded as the percentage of maximum stimulator output required to elicit a motor-evoked potential (MEP). RMT is measured during muscle relaxation, while AMT is measured during a 10-20% maximum voluntary contraction. | ClinicalTrials.gov |
| Primary | Cortical Silent Period (CSP) | Baseline (Week 0) and post-intervention (Week 13) | Cortical silent period duration is measured in milliseconds using TMS during sustained muscle contraction. CSP is determined from the interval between the end of the MEP response and the recovery of rectified electromyographic activity to the predefined baseline level. | ClinicalTrials.gov |
| Primary | Short-Interval Intracortical Inhibition (SICI) and Intracortical Facilitation (ICF) | Baseline (Week 0) and post-intervention (Week 13) | Intracortical inhibition and facilitation are assessed using paired-pulse TMS. The ratio of conditioned to unconditioned MEP amplitudes is calculated. SICI is measured at interstimulus intervals of 1, 2, 3, and 5 ms, while ICF is measured at 8, 10, 12, and 15 ms. | ClinicalTrials.gov |
| Primary | Motor-Evoked Potential Input/Output Curve | Baseline (Week 0) and post-intervention (Week 13). | Corticospinal excitability is assessed by recording MEP amplitudes across TMS stimulus intensities ranging from 90% to 150% of resting motor threshold in 10% increments. Mean peak-to-peak MEP amplitudes are calculated and fitted using a Boltzmann sigmoid function to estimate the plateau amplitude. | ClinicalTrials.gov |
| Primary | Plasma and Sweat Extracellular Vesicle Concentration | Baseline (Week 0) and post-intervention (Week 13). | Extracellular vesicles isolated from plasma and sweat samples are quantified using nanoparticle tracking analysis (NTA). Vesicle concentration is reported as particles per milliliter (particles/mL). | ClinicalTrials.gov |
| Primary | Plasma and Sweat Extracellular Vesicle Size Distribution | Baseline (Week 0) and post-intervention (Week 13) | Extracellular vesicle size distribution in plasma and sweat samples is assessed using nanoparticle tracking analysis. The modal vesicle diameter is reported in nanometers, together with the proportion of particles within the 30-150 nm size range. | ClinicalTrials.gov |
| Primary | Proteomic Cargo of Plasma and Sweat Extracellular Vesicles | Baseline (Week 0) and post-intervention (Week 13) | Protein cargo in plasma and sweat extracellular vesicles is characterized using high-throughput mass spectrometry. Protein profiles are reported as relative protein abundance or presence/absence. Protein identification and functional interpretation are performed using the UniProt human proteome and STRING protein-protein interaction and pathway analyses. | ClinicalTrials.gov |
| Primary | Quadriceps Isokinetic Strength | Baseline (Week 0) and post-intervention (Week 13) | Quadriceps muscle strength is assessed as peak torque during concentric knee extension at angular velocities of 60, 180, and 300 degrees per second. The highest torque across maximal repetitions at each speed is recorded in Newton-meters (Nm). | ClinicalTrials.gov |
| Primary | Shoulder Isokinetic Strength | Baseline (Week 0) and post-intervention (Week 13) | Shoulder muscle strength is assessed as peak torque during concentric shoulder through a range of motion of 0-150 degrees at angular velocities of 60 and 120 degrees per second. Peak torque is reported in Newton-meters (Nm). | ClinicalTrials.gov |
| Primary | Isometric Handgrip Strength | Baseline (Week 0) and post-intervention (Week 13) | Maximum voluntary isometric handgrip force of the dominant hand is measured. The highest value from three trials is recorded in kilograms (kg) or converted to Newtons (N). | ClinicalTrials.gov |
| Primary | Time to Peak Hand Velocity | Baseline (Week 0) and post-intervention (Week 13) | Hand movement cycles are identified using hand-marker trajectories. Peak resultant hand velocity is determined within each movement cycle, and the time at which peak velocity occurs is expressed as a percentage of the normalized movement cycle (0-100%). | ClinicalTrials.gov |
| Primary | Craniovertebral Angle (CVA) | Baseline (Week 0) and post-intervention (Week 13) | Craniovertebral angle is measured in degrees in the sagittal plane between a horizontal line passing through the C7 vertebral marker and a line connecting the C7 marker to the tragus marker. | ClinicalTrials.gov |
| Secondary | Body Fat Percentage | Baseline (Week 0) and post-intervention (Week 13) | Body fat percentage is assessed using bioelectrical impedance analysis (BIA). The proportion of total body mass consisting of fat is recorded as a percentage (%). | ClinicalTrials.gov |
| Secondary | Skeletal Muscle Mass | Baseline (Week 0) and post-intervention (Week 13) | Skeletal muscle mass is assessed using bioelectrical impedance analysis (BIA). The estimated mass of skeletal muscles is recorded in kilograms (kg). | ClinicalTrials.gov |
| Secondary | Fat-Free Mass | Baseline (Week 0) and post-intervention (Week 13) | Fat-free mass is assessed using bioelectrical impedance analysis (BIA). The estimated mass of body components excluding fat is recorded in kilograms (kg). | ClinicalTrials.gov |
| Secondary | Physical Activity Level (International Physical Activity Questionnaire) | Baseline (Week 0) and post-intervention (Week 13) | Physical activity is assessed using the International Physical Activity Questionnaire (IPAQ). Total physical activity is calculated in metabolic equivalent minutes per week (MET-min/week) according to the IPAQ scoring protocol. The results are used to confirm participant classification into active and sedentary groups. | ClinicalTrials.gov |
| Secondary | Musculoskeletal Discomfort (Nordic Musculoskeletal Questionnaire) | Baseline (Week 0) and post-intervention (Week 13) | Musculoskeletal discomfort is assessed using the Nordic Musculoskeletal Questionnaire (NMQ). Participants report musculoskeletal problems across nine body regions during the preceding seven days. Point prevalence is calculated as the number of participants reporting problems divided by the total number of participants, expressed as a percentage. | ClinicalTrials.gov |
| Secondary | Ergonomic Risk Assessment (Rapid Upper Limb Assessment) | Baseline (Week 0) and post-intervention (Week 13) | Ergonomic risk is evaluated using the Rapid Upper Limb Assessment (RULA). Postures of the upper arms, lower arms, wrists, neck, trunk, and legs are assessed together with muscle-use and force scores to calculate a grand score ranging from 1 to 7. | ClinicalTrials.gov |
| Secondary | Musculoskeletal Discomfort Severity (Cornell Musculoskeletal Discomfort Questionnaire) | Baseline (Week 0) and post-intervention (Week 13). | Musculoskeletal discomfort severity is assessed using the Cornell Musculoskeletal Discomfort Questionnaire (CMDQ). Scores are calculated for each body region by multiplying discomfort frequency, severity, and work interference. Scores range from 0 to 90 per body region. | ClinicalTrials.gov |
| Secondary | Global Rating of Change | Post-intervention (Week 13) | Participants' perceived overall progress is assessed using the Global Rating of Change (GRoC) scale, ranging from -7 (a very great deal worse) to +7 (a very great deal better), with 0 indicating no change. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 7
The papers the trial lists on ClinicalTrials.gov.
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)